UPMC Hillman Cancer Center is part of the UPMC family.

Cancer Immunotherapeutics Center

Immunotherapy and Drug Development Center

UPMC designed the Immunotherapy and Drug Development Center (IDDC) to speed the most promising new immunotherapies toward large clinical trials.

A diverse team conducts early-phase trials on all aspects of immunotherapy across the spectrum of cancer.

Experts at the IDDC treat solid organ tumors and lymphomas that haven't responded to standard treatment. We leverage UPMC Hillman Cancer Center's science to launch researcher-lead clinical trials.

Through this teamwork, we offer access to treatments never available before and can bring customized care to more people.

To learn more about the IDDC or to make an appointment, contact the IDDC at 412-623-7994 or IDDCreferrals@upmc.edu.

Current Clinical Trials at the IDDC

We're now enrolling people in more than 30 early-phase trials.

These trials address the full range of immunotherapy methods, including:

  • Immune checkpoint antibodies.
  • Small-molecule innate immune agonists.
  • Bispecific immune therapies.
  • Cellular products.
  • Immunometabolism modifiers.

Protocol: 19-052
Title: A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients

Protocol: 19-063
Title: Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy in Patients with Lymphoma or Solid Tumor

Protocol: 19-065
Title: A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (POD1UM-102)

Protocol: 19-066
Title: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms

Protocol: 19-074
Title: A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

Protocol: 19-078
Title: ADaptiVe Biomarker Trial that InformS Evolution of Therapy (ADVISE)

Protocol: 19-079
Title: A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms

Protocol: 19-081
Title: "A Phase I Study of BMS-986301 Monotherapy and Combination Therapy with Nivolumab and Ipilimumab in Participants with Advanced Solid Cancers"

Protocol: 19-095
Title: A Phase 1/1b multicenter study to evaluate the humanized anti-CD 73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult subjects with advanced cancers

Protocol: 19-097
Title: A Phase Ib/II study of ARRY-614 plus either nivolumab or ipilimumab in advanced melanoma, renal cell carcinoma, and solid tumors

Protocol: 19-098
Title: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)

Protocol: 19-099
Title: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

Protocol: 19-100
Title: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Protocol: 19-101
Title: A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors

Protocol: 19-112
Title: Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling

Protocol: 19-113
Title: Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients having solid tumors including but not limited to non-small cell lung cancer or head and neck squamous cell carcinoma (ACTengine IMA201-101)

Protocol: 19-114
Title: Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors (ACTengine® IMA202-101)

Protocol: 19-115
Title: Phase 1 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)

Protocol: 19-123
Title: A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Protocol: 19-124
Title: "A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect on Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors"

Protocol: 19-160
Title: An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects with Advanced Solid Tumors or Lymphomas - INSTAL-101

Protocol: 19-161
Title: A Phase 1, Open-label, Multicenter Study of SYNB1891 Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors and Lymphoma Alone and in Combination with Atezolizumab

Protocol: 19-169
Title: A Phase 1, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Protocol: 19-177
Title: Phase I/II Open-Label, Safety and Preliminary Efficacy Study of MRx0518 In Combination with Pembrolizumab In Patients with Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors

Protocol: 19-199
Title: Phase 1 Study of BDC-1001 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced and HER2 Expressing Solid Tumors

Protocol: 19-203
Title: A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies

Protocol: 20-015
Title: A phase 1, open-label, multiple-ascending dose study to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors

Protocol: 20-025
Title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

Protocol: 20-040
Title: Phase 1/2 Study of RTX-240 Monotherapy

Protocol: 20-051
Title: A phase 1 study of SGN-CD228A in select advanced solid tumors

Protocol: 20-061
Title: An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

Protocol: 20-062
Title: Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination with Budigalimab and/or Chemotherapy in Subjects with Advanced Solid Tumors

Protocol: 20-080
Title: "A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors "

Protocol: 20-081
Title: A Phase 1/1b, Open-Label, Dose Escalation and Expansion Study of SBT6050 in Subjects with Advanced Solid Tumors Expressing HER2

Protocol: 20-086
Title: An open-label study of ALPN-202 in subjects with advanced malignancies

Protocol: 20-088
Title: A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

Learn more at the UPMC Hillman Cancer Center Research website.

Experts at the IDDC

Co-Directors: Jason Luke, MD, and Liza Villaruz, MD.

Contact the IDDC

To make a referral or an appointment, contact IDDC at 412-623-7994 or IDDCreferrals@upmc.edu.